Quanterix Corp (Quanterix) is a life sciences company that develops and markets an ultra-sensitive digital immunoassay platform. It offers a biomarker detection system, antibodies and ELISA kits, a bead-based immunoassay platform and homebrew assays. Quanterix provides protein biomarker testing and custom assay development services. It markets diagnostics technology under the brands of Simoa, HD-X Analyzer, SR-X, SP-X Imaging and Analysis System and Uman NF-Light. Its products find application in detecting central nervous system (CNS), oncology, and cardiac biomarkers at ultra-low levels; measuring inflammatory markers in normal and disease samples, and cytokine levels and profiles in non-critical and critical COVID-19 patients. The company operates in the Netherlands, Sweden, Hong Kong and China. Quanterix is headquartered in Billerica, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Quanterix Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Quanterix Corp Company Overview
- Quanterix Corp Company Snapshot
- Quanterix Corp Pipeline Products and Ongoing Clinical Trials Overview
- Quanterix Corp - Pipeline Analysis Overview
- Quanterix Corp - Key Facts
- Quanterix Corp - Major Products and Services
- Quanterix Corp Pipeline Products by Development Stage
- Quanterix Corp Pipeline Products Overview
- AccuPSA Test
- AccuPSA Test Product Overview
- ADVIA Centaur sNFL Assay - Multiple Sclerosis
- ADVIA Centaur sNFL Assay - Multiple Sclerosis Product Overview
- ALS Monitoring Test
- ALS Monitoring Test Product Overview
- Antigen Detection Assay - Tuberculosis
- Antigen Detection Assay - Tuberculosis Product Overview
- Blood Based Biomarker Panel - Mood Disorder
- Blood Based Biomarker Panel - Mood Disorder Product Overview
- Blood Based Biomarker Test - Frontotemporal Dementia
- Blood Based Biomarker Test - Frontotemporal Dementia Product Overview
- Blood Based Biomarker Test - Lewy Body Dementia
- Blood Based Biomarker Test - Lewy Body Dementia Product Overview
- Blood Based Biomarker Test - Parkinson’s Disease
- Blood Based Biomarker Test - Parkinson’s Disease Product Overview
- Blood Based Test - Alzheimer's Disease
- Blood Based Test - Alzheimer's Disease Product Overview
- Diagnostic Blood Test - Huntington’s Disease
- Diagnostic Blood Test - Huntington’s Disease Product Overview
- Digital ELISA - Crohn’s Disease
- Digital ELISA - Crohn’s Disease Product Overview
- Digital ELISA Assay - C. Difficile
- Digital ELISA Assay - C. Difficile Product Overview
- Drug Monitoring Blood Test - Alzheimer's Disease
- Drug Monitoring Blood Test - Alzheimer's Disease Product Overview
- MS Drug Monitoring Test (NfL)
- MS Drug Monitoring Test (NfL) Product Overview
- Neuro Side Effect Test
- Neuro Side Effect Test Product Overview
- NeuroFilament Light Assay - Alzheimer’s Disease
- NeuroFilament Light Assay - Alzheimer’s Disease Product Overview
- P-Tau181 V2 Kit
- P-Tau181 V2 Kit
- POC Device - Neurological Injuries
- POC Device - Neurological Injuries Product Overview
- Simoa 3.0
- Simoa 3.0 Product Overview
- Simoa 4.0
- Simoa 4.0 Product Overview
- Simoa Antibody Test - COVID-19
- Simoa Antibody Test - COVID-19 Product Overview
- SiMoA HD-1 Analyzer - Botulinum Toxin Assay
- SiMoA HD-1 Analyzer - Botulinum Toxin Assay Product Overview
- Simoa HD-1 Analyzer - Lung Cancer
- Simoa HD-1 Analyzer - Lung Cancer Product Overview
- Simoa HD-1 Analyzer - Pancreatic Cancer
- Simoa HD-1 Analyzer - Pancreatic Cancer Product Overview
- SiMoA HD-1 Analyzer - Prostate Cancer Assay
- SiMoA HD-1 Analyzer - Prostate Cancer Assay Product Overview
- Simoa SARS-Cov-2 Antigen Test
- Simoa SARS-Cov-2 Antigen Test Product Overview
- Simoa-DMF Analyzer - COVID-19
- Simoa-DMF Analyzer - COVID-19 Product Overview
- Simoa-DMF Analyzer - Influenza A/B
- Simoa-DMF Analyzer - Influenza A/B Product Overview
- sNfL Assay
- sNfL Assay Product Overview
- Tau-SIMOA Assay - ADRD
- Tau-SIMOA Assay - ADRD Product Overview
- Tau-SIMOA Assay - Alzheimer’s Disease
- Tau-SIMOA Assay - Alzheimer’s Disease Product Overview
- TBI Severity Dx
- TBI Severity Dx Product Overview
- Ultrasensitive Test - Alzheimer’s Disease
- Ultrasensitive Test - Alzheimer’s Disease Product Overview
- Quanterix Corp - Key Competitors
- Quanterix Corp - Key Employees
- Quanterix Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Quanterix Corp, Recent Developments
- May 07, 2024: Quanterix Releases Financial Results for the First Quarter of 2024
- Mar 21, 2024: Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
- Mar 04, 2024: Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
- Feb 26, 2024: Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease
- Nov 06, 2023: Quanterix Releases Operating Results for Third Quarter 2023
- Oct 24, 2023: Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Diseasequanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease
- Aug 07, 2023: Quanterix Releases Operating Results For Second Quarter 2023
- Jul 31, 2023: Quanterix’s Simoa Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients
- Jul 07, 2023: Quanterix introduces new blood test for Alzheimer’s diagnosis
- Jul 06, 2023: Quanterix Launches Lucentad Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer’s Disease in Patients
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Quanterix Corp Pipeline Products and Ongoing Clinical Trials Overview
- Quanterix Corp Pipeline Products by Equipment Type
- Quanterix Corp Pipeline Products by Indication
- Quanterix Corp, Key Facts
- Quanterix Corp, Major Products and Services
- Quanterix Corp Number of Pipeline Products by Development Stage
- Quanterix Corp Pipeline Products Summary by Development Stage
- AccuPSA Test - Product Status
- AccuPSA Test - Product Description
- ADVIA Centaur sNFL Assay - Multiple Sclerosis - Product Status
- ADVIA Centaur sNFL Assay - Multiple Sclerosis - Product Description
- ALS Monitoring Test - Product Status
- ALS Monitoring Test - Product Description
- Antigen Detection Assay - Tuberculosis - Product Status
- Antigen Detection Assay - Tuberculosis - Product Description
- Blood Based Biomarker Panel - Mood Disorder - Product Status
- Blood Based Biomarker Panel - Mood Disorder - Product Description
- Blood Based Biomarker Test - Frontotemporal Dementia - Product Status
- Blood Based Biomarker Test - Frontotemporal Dementia - Product Description
- Blood Based Biomarker Test - Lewy Body Dementia - Product Status
- Blood Based Biomarker Test - Lewy Body Dementia - Product Description
- Blood Based Biomarker Test - Parkinson’s Disease - Product Status
- Blood Based Biomarker Test - Parkinson’s Disease - Product Description
- Blood Based Test - Alzheimer's Disease - Product Status
- Blood Based Test - Alzheimer's Disease - Product Description
- Diagnostic Blood Test - Huntington’s Disease - Product Status
- Diagnostic Blood Test - Huntington’s Disease - Product Description
- Digital ELISA - Crohn’s Disease - Product Status
- Digital ELISA - Crohn’s Disease - Product Description
- Digital ELISA Assay - C. Difficile - Product Status
- Digital ELISA Assay - C. Difficile - Product Description
- Drug Monitoring Blood Test - Alzheimer's Disease - Product Status
- Drug Monitoring Blood Test - Alzheimer's Disease - Product Description
- MS Drug Monitoring Test (NfL) - Product Status
- MS Drug Monitoring Test (NfL) - Product Description
- Neuro Side Effect Test - Product Status
- Neuro Side Effect Test - Product Description
- NeuroFilament Light Assay - Alzheimer’s Disease - Product Status
- NeuroFilament Light Assay - Alzheimer’s Disease - Product Description
- P-Tau181 V2 Kit - Product Description
- P-Tau181 V2 Kit - Product Description
- POC Device - Neurological Injuries - Product Status
- POC Device - Neurological Injuries - Product Description
- Simoa 3.0 - Product Status
- Simoa 3.0 - Product Description
- Simoa 4.0 - Product Status
- Simoa 4.0 - Product Description
- Simoa Antibody Test - COVID-19 - Product Status
- Simoa Antibody Test - COVID-19 - Product Description
- SiMoA HD-1 Analyzer - Botulinum Toxin Assay - Product Status
- SiMoA HD-1 Analyzer - Botulinum Toxin Assay - Product Description
- Simoa HD-1 Analyzer - Lung Cancer - Product Status
- Simoa HD-1 Analyzer - Lung Cancer - Product Description
- Simoa HD-1 Analyzer - Pancreatic Cancer - Product Status
- Simoa HD-1 Analyzer - Pancreatic Cancer - Product Description
- SiMoA HD-1 Analyzer - Prostate Cancer Assay - Product Status
- SiMoA HD-1 Analyzer - Prostate Cancer Assay - Product Description
- Simoa SARS-Cov-2 Antigen Test - Product Status
- Simoa SARS-Cov-2 Antigen Test - Product Description
- Simoa-DMF Analyzer - COVID-19 - Product Status
- Simoa-DMF Analyzer - COVID-19 - Product Description
- Simoa-DMF Analyzer - Influenza A/B - Product Status
- Simoa-DMF Analyzer - Influenza A/B - Product Description
- sNfL Assay - Product Status
- sNfL Assay - Product Description
- Tau-SIMOA Assay - ADRD - Product Status
- Tau-SIMOA Assay - ADRD - Product Description
- Tau-SIMOA Assay - Alzheimer’s Disease - Product Status
- Tau-SIMOA Assay - Alzheimer’s Disease - Product Description
- TBI Severity Dx - Product Status
- TBI Severity Dx - Product Description
- Ultrasensitive Test - Alzheimer’s Disease - Product Status
- Ultrasensitive Test - Alzheimer’s Disease - Product Description
- Quanterix Corp, Key Employees
- Quanterix Corp, Subsidiaries
- Glossary
- Quanterix Corp Pipeline Products by Equipment Type
- Quanterix Corp Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Seer Inc
- Bio-Techne Corp
- SomaLogic Inc
- Gyros US Inc
- Meso Scale Discovery
- Thermo Fisher Scientific Inc
- Bio-Rad Laboratories Inc
- Olink Holding AB
- MilliporeSigma
